Eli Lilly: FDA approves Omvoh for Crohn's disease
(CercleFinance.com) - Eli Lilly announces that the US FDA has approved Omvoh (mirikizumab) for the treatment of moderate to severe Crohn's disease in adults.
Already approved in 2023 for ulcerative colitis, Omvoh targets interleukin-23p19 to reduce intestinal inflammation.
Approval was based on a Phase III study in which 53% of patients achieved clinical remission after one year, compared with 36% on placebo.
Omvoh also showed promising results in terms of intestinal healing and long-term remission.
Lilly has submitted applications for worldwide approval and offers a patient support program to facilitate access to treatment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Already approved in 2023 for ulcerative colitis, Omvoh targets interleukin-23p19 to reduce intestinal inflammation.
Approval was based on a Phase III study in which 53% of patients achieved clinical remission after one year, compared with 36% on placebo.
Omvoh also showed promising results in terms of intestinal healing and long-term remission.
Lilly has submitted applications for worldwide approval and offers a patient support program to facilitate access to treatment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.